A study by Hausmann et al. (2015) [33] investigated the potential of SGK3 as a therapeutic target in MM by examining its role in oncogenic signalling, either independently or in cooperation with Akt, using three MM cell lines. This evidence concerns the gene AKT1 and Miyoshi myopathy.